1101840-81-6

Basic information

• Product Name: (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol
• Synonyms: (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol
• CAS NO: 1101840-81-6
• Molecular Weight: 217.311
• Mol File: 1101840-81-6.mol

Chemical Properties

• CAS DataBase Reference: (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol(1101840-81-6)
• EPA Substance Registry System: (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol(1101840-81-6)

Safety Data

• Hazardous Substances Data: 1101840-81-6(Hazardous Substances Data)

Upstream product

• 1101840-77-0 6-benzyl-6-aza-spiro[2.5]octan-4-one hydrochloride 
• 1101840-76-9 1-[2-(benzyl-tert-butoxycarbonylmethyl-amino)-ethyl]-cyclopropanecarboxylic acid tert-butyl ester 
• 452911-09-0 tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate 
• 7662-76-2 tert-butyl 2-(benzylamino)acetate 
• 100-46-9 benzylamine 
• 108546-98-1 1-allyl-cyclopropanecarboxylic acid tert-butyl ester 

Downstream Products

• 1290050-27-9 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid (3-chloro-phenyl)-amide 
• 1290050-56-4 (S)-4-[(R,S)-3-hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3-chloro-4-trifluoromethyl-phenyl)-amide 
• 1290049-14-7 (S)-4-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3,4-dichloro-phenyl)-amide 
• 1290049-74-9 (S)-4-[(E)-3-(3-Chloro-4-fluoro-phenyl)-acryloyl]-1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-3-methyl-piperazin-2-one 
• 1290048-74-6 (S)-4-[(R,S)-3-Hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid benzyl ester 
• 1290048-29-1 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid benzyl ester 
• 1103501-89-8 (S)-6-aza-spiro[2.5]octan-4-ol hydrochloride 
• 1103501-90-1 (S)-6-aza-spiro[2.5]octan-4-ol 

Relevant articles and documents

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.